Phase 2 Studies Show OCA-Bezafibrate Achieves Biochemical Remission, ALP Reduction
Topline data from Study 747-213 and a planned interim analysis from Study 747-214 were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases.